Regulatory Analysis
FDA regulatory intelligence, warning letter breakdowns, and actionable analysis for brands across all FDA-regulated categories.
Weekly FDA Roundup: a 16-flavor ice pop recall, a food-dye cleanup, and 15 warning letters, July 18–24, 2026
FDA's highest-risk recall of the week hit a box of paletas, while the agency revoked one petroleum food dye, moved against another, and pulled 1.5 million dozen eggs.
Read article →
Weekly FDA Roundup: Taylor Farms pulls all its Mexican iceberg lettuce, a recalled anesthetic keeps surfacing in surgical kits, and 13 warning letters land in a day, July 11–17, 2026
A Cyclospora outbreak forced Taylor Farms to recall every head of Central Mexico iceberg across 27 states, while a recalled Huons anesthetic pulled two more surgical kit lines off the market.
Read more →
Weekly FDA Roundup: botulism in infant formula, a ketamine warning-letter sweep, and a growing convenience-kit thread, July 4–10, 2026
FDA logged 44 actions this week, led by a Class I recall of Nara Organics infant formula tied to four confirmed infant botulism cases, plus 15 warning letters to online ketamine sellers.
Read more →
Weekly FDA Roundup: seven million insulin pods recalled, a wave of Salmonella food recalls, and ten warning letters, June 27–July 3, 2026
FDA's most serious actions this week were four Class I device recalls, led by roughly 7 million Insulet Omnipod insulin pods, alongside a cluster of Class I food recalls and ten warning letters.
Read more →
Weekly FDA Roundup: Amazon gets a warning letter, three Class I food recalls, and a foreign tobacco crackdown, June 20–26, 2026
FDA posted 20 warning letters in a single day, and the biggest name on the list was Amazon itself. Plus three Class I food recalls and a proposed rule targeting foreign tobacco makers.
Read more →
Weekly FDA Roundup: 25 telehealth GLP-1 warning letters, an infant formula botulism recall, and four Class I food recalls, June 13-19, 2026
FDA posted 25 warning letters to telehealth firms selling compounded GLP-1 drugs in one day, plus four Class I food recalls and an all-lots infant formula recall tied to infant botulism.
Read more →
Weekly FDA Roundup: 22 Class I recalls, an infant formula toxin, and a new sunscreen ingredient, June 6–12, 2026
FDA classified 22 recalls Class I in a single week, nearly half of May's total, led by an infant formula pulled over a heat-stable toxin and a Salmonella wave traced to dry milk powder.
Read more →
Weekly FDA Roundup: a milk powder cascade drives eight Class I recalls, eleven warning letters land in a day, and FDA moves to speed gene therapies, May 30–June 5, 2026
Eight Class I recalls hit this week, most tracing to one Salmonella-contaminated milk powder or a milk allergen. FDA also posted eleven warning letters in a single day.
Read more →
Weekly FDA Roundup: one tainted dairy ingredient drives 36 Class I recalls, two supplement makers face botulism scares, and Insulet pulls 7 million insulin pods, May 23–29, 2026
One Salmonella-tainted batch of milk powder from California Dairies drove 36 of the week's 38 Class I recalls, from Ghirardelli cocoa to trail mix, while two supplement makers faced botulism scares.
Read more →
Weekly FDA Roundup: a stent graft tied to three deaths, an 11-letter tobacco sweep, and the first HDV drug, May 16–22, 2026
FDA logged 59 actions this week, led by a Class I stent graft recall linked to three deaths, four Class I recalls in all, and 11 warning letters to online tobacco sellers.
Read more →
Weekly FDA Roundup: one milk powder triggers a Class I cascade, Raw Farm's E. coli cheddar returns, and FDA reopens BHT, May 9–15, 2026
A single Salmonella-tainted milk powder from California Dairies drove a wave of Class I recalls across Griffith Foods, Chick-fil-A, and Costco suppliers, while Raw Farm's E. coli cheddar returned.
Read more →
Weekly FDA Roundup: A Class I Pacemaker Recall, a 23-Warning-Letter Day, and the First Flavored E-Cigarette Ever Authorized, May 2–8, 2026
FDA’s most serious action of the week was a battery. A Class I recall hit six Boston Scientific pacemaker families while 23 warning letters landed in a single day and the agency cleared its first-ever flavored e-cigarette.
Read more →
Weekly FDA Roundup: GLP-1 Compounding Hits a Wall, Two Class I Recalls in Diabetes Care, and the First Non-Antipsychotic for Dementia Agitation, April 25 to May 1, 2026
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Class I recalls for Trividia TRUE METRIX and Insulet Omnipod 5. Auvelity wins first non-antipsychotic dementia agitation approval. Plus three CGMP warning letters.
Read more →
Weekly FDA Roundup: A 14-Warning-Letter Day, a New Medicare Coverage Pathway, and the First Gene Therapy for Deafness, April 18–24, 2026
Fourteen warning letters in a single day, the new RAPID coverage pathway, and the first gene therapy for genetic deafness. What sponsors, compounders, and device kit-makers need to know from April 18–24.
Read more →
Weekly FDA Roundup: April 11–17, 2026
Seven Class I device actions in three days including two tied to the same defective syringe. CDER sweeps four online pharmacies. Purolea Cosmetics Lab cited for using AI to generate compliance docs without Quality Unit review. Plus clinical trial disclosure push and a TRT label-expansion signal.
Read more →
Weekly FDA Roundup: April 4–10, 2026
FDA drops 7 GLP-1 warning letters in one coordinated sweep — the enforcement focus has broadened from compounders and telehealth to raw peptide vendors and eBay arbitrage sellers. Plus three device early alerts, a DSCSA fraud warning at a med spa, and a Wellcovorin NDA withdrawal.
Read more →
Weekly FDA Roundup: Oral GLP-1 approved in 50 days, CGMP cluster, and steroid-spiked supplements
Eli Lilly's Foundayo became the first new molecular entity approved under the FDA's CNPV pilot — 50 days, 294 days ahead of its PDUFA date. Three CGMP warning letters landed the same day, and a supplement recall surfaced undeclared prescription steroids in weight-gain capsules. March 27 to April 3, 2026.
Read more →
Weekly FDA Roundup: Hospital Drug Mix-Up, Natural Dye Delays, and a Cancer "Vaccine" Warning — Week of March 21–28, 2026
Amneal Pharmaceuticals recalls magnesium sulfate pouches after a tranexamic acid mix-up reaches hospitals nationwide. FDA delays beetroot red and spirulina extract approvals indefinitely. ImmunityBio warned over "cancer vaccine" claims for bladder cancer drug ANKTIVA. Plus six warning letters, two Class I device recalls, and two rare pediatric drug approvals.
Read more →
Weekly FDA Roundup: Higher-Dose Wegovy Fast-Tracked, Device Recalls Report Injuries and a Death, Week of March 14-20, 2026
Higher-dose Wegovy approved in 54 days via the CNPV program. Two device recalls tied to 22 injuries and one death. Made Fresh Salads pulls 14 cream cheese products for Listeria. Plus 11 warning letters.
Read more →
Weekly FDA Enforcement Roundup — March 6–13, 2026
13 warning letters. A new draft guidance on 483 responses. 61 drug approvals pulled. The AEMS launch. And Novo Nordisk in the hot seat over unreported GLP-1 deaths.
Read more →
FDA Recall List, March 2026: Undeclared Allergens, Hidden Prescription Drugs, and Plastic Contamination
The FDA recall list for late February and early March 2026 shows three clear patterns: an allergen labeling wave, prescription drugs in supplement products, and physical contamination at scale.
Read more →
Weekly FDA Roundup: Compounding Crackdown and Device Safety Alerts — Week of Feb 21–28, 2026
55 FDA actions in one week: a landmark framework for ultra-rare genetic disease therapies, a compounding pharmacy warning letter previewing the GLP-1 enforcement surge, four medical device safety alerts from four manufacturers, and two recalls for undeclared prescription drugs in supplements.
Read more →
Weekly FDA Roundup: US-EU Pharma Deal Revoked, Blood Glucose Device Death, and 8 Class I Recalls — Week of Feb 14–21, 2026
FDA revokes the US-EU pharmaceutical GMP mutual recognition agreement effective March 23, while a blood glucose correction links 114 injuries and one death to an error-code flaw, and five simultaneous Class I recalls sweep a hummus brand.
Read more →
Weekly FDA Roundup: Hormone Therapy Gets a New Label, Botulism Stalks the Supplement Aisle — Week of Feb 7–14, 2026
FDA removed MHT boxed warnings, approved a first-of-its-kind pancreatic cancer device, launched a BHA reassessment, and fielded 51 recalls — including a 12-SKU Clostridium botulinum sea moss gel cluster.
Read more →
Weekly FDA Roundup: GLP-1 Crackdown, Abbott's Triple Hit, and the Artificial Colors Pivot — Week of Jan 31–Feb 7, 2026
FDA signals the end of the GLP-1 compounding era, Abbott Diabetes Care faces three enforcement actions in 48 hours, and new artificial color policy clears the path for natural alternatives.
Read more →
Weekly FDA Roundup: Flawed Blood Lead Test, FSVP Enforcement Wave, and 22 Recalls — Week of January 26, 2026
FDA's week of Jan 24–31 brought 35 actions: a warning letter targeting a pediatric blood lead testing device with false positives, four FSVP letters in one day, and 22 recalls dominated by allergen and labeling failures.
Read more →
Weekly FDA Roundup: MAHA Takes Shape in Policy, 28 Recalls, and a Wound Care Alert — Week of Jan 17–24, 2026
FDA issued a MAHA-driven gluten labeling RFI, reported ImportShield efficiency gains, and posted five warning letters — alongside 28 recalls and a serious wound care device alert from Integra LifeSciences.
Read more →
Weekly FDA Roundup: Pecorino Romano Class I Recall Sweep and CGT Flexibility Shift — Week of Jan 10–17, 2026
A coordinated 8-product Class I recall from Ambriola Co. swept multiple Pecorino Romano brands; FDA formalized CMC flexibility for cell and gene therapies under Commissioner Makary.
Read more →
Weekly FDA Roundup: Supplement Adulteration, CGMP Cluster, and Nicotine Pouch Crackdown — Week of January 3–10, 2026
FDA opened 2026 with a targeted enforcement week: a dietary supplement recalled for undeclared meloxicam, three CGMP warning letters to OTC manufacturers on the same day, and two tobacco retailers cited for unauthorized nicotine pouches.
Read more →
Weekly FDA Roundup: PFAS in Cosmetics, a Children's Supplement Spiked with an Unapproved Drug, and a Holiday Recall Wave — Week of Dec 27–Jan 3
FDA's MoCRA report finds insufficient safety data for most PFAS in cosmetics; a children's growth supplement contained hidden ibutamoren; seven herbal products recalled in one sweep.
Read more →What if this analysis was about YOUR products?
Policy Canary monitors the FDA for your specific products — by name, by ingredient, by facility. Start your free trial.
Start Free Trial